Metis TechBio Co., Ltd. (HKG:7666)

Market Cap	14.91B
Revenue (ttm)	116.85M +6,985.0%
Net Income	-436.04M
EPS	-4.63
Shares Out	1.15B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	460,500
Open	12.71
Previous Close	12.94
Day's Range	12.50 - 13.22
52-Week Range	12.50 - 29.98
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Metis TechBio

Metis TechBio Co., Ltd. engages in research and development of AI-empowered nanomaterial for the delivery and application of active agents across carbon-based life forms in Chinese Mainland and United States. It develops NanoForge, a suite of synergistic technologies that includes novo lipid library, AI foundational models, METiSAIAgent, quantum chemistry and molecular dynamics simulations, and AI-driven screening platforms. The company also develops specialized platforms, such as AiTEM, AiLNP and AiRNA that simulate, predict, and interpret nan...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2020
• Country: China
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 7666

Financial Performance

In 2025, Metis TechBio's revenue was 105.00 million, an increase of 6985.02% compared to the previous year's 1.48 million. Losses were -391.84 million, -21.51% less than in 2024.

Financial numbers in CNY